Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
about
Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to GoTargeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptidesEGFR Tyrosine 845 Phosphorylation-Dependent Proliferation and Transformation of Breast Cancer Cells Require Activation of p38 MAPK.Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancerPharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer.Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity.The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signalingTargeting the function of the HER2 oncogene in human cancer therapeutics.Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancerA phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancerMesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical modelDisclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancerTissue microarrays: bridging the gap between research and the clinic.Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity.Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets.Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.A validated tumorgraft model reveals activity of dovitinib against renal cell carcinomaPhase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer.Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer ProgressionModulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.Small molecule signal transduction inhibitors for the treatment of solid tumors.Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of MetSensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activityHER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.A prognostic risk model for patients with triple negative breast cancer based on stromal natural killer cells, tumor-associated macrophages and growth-arrest specific protein 6.Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancerDevelopment of Solid Self-Emulsifying Formulation for Improving the Oral Bioavailability of Erlotinib.Anti-epidermal growth factor receptor strategies for advanced breast cancer.A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cellsTargeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases.
P2860
Q26772925-8855C54F-4130-49E7-BE15-D6AB9F4CB200Q28486075-E6BE7D4B-D43C-4F0B-AAF6-16606E7D0B56Q30424563-66A83795-F959-4AA2-B86A-B6849F87C586Q30484735-A39630A2-B65C-4EF2-8371-9470A26CB1EAQ33551899-161F5557-EB7C-4E10-B3AB-6D9368740278Q33583253-C68DF8F1-9DE3-428E-A4B3-6DEBD7DB112AQ33728406-D871005B-555E-409D-B3F8-04757FC9E85AQ33990934-066800DF-1EB6-46BC-96CB-7E2506A4844BQ34549722-2C698860-D85B-4939-BABA-CACBB5240C53Q34631999-1358D6D3-1A80-4EAA-93B5-2891511B10CDQ34708815-C1A896E6-DAA3-43F0-9194-892B4A178B47Q34766486-709254CD-0041-4584-A3E4-EB26E296543FQ34775370-B84E7203-D6EC-45E0-8852-C8375A34E6ACQ34910416-ABDAF2E5-0BA7-43A3-B953-E87BECA0D8ACQ35007782-D612ABCA-243A-4265-A4C4-5153361DBD2DQ35313206-BE321803-3F2B-4B7E-9399-FB3812D6A413Q35571884-085C2AD5-D8E6-458A-86A4-848C7E4A0918Q35691935-664C70F4-F7FA-4B39-8DD4-AD2565BC3284Q36083065-422B9387-F1EC-4B0B-84D0-16F4DE6F4462Q36184792-9B0BF821-F1A2-48AB-B5AA-078A7128B549Q36235591-80A1769F-105A-47BE-81D7-69E1ACAF8F64Q36334889-AF830563-CC8C-404D-AC76-B985FAA6FFF0Q36410371-55968941-D005-4165-AD3A-D875FABE00FAQ36606040-F6A7F2CD-7807-43C6-B47E-59E307D316ECQ36614598-75CCA428-19F8-4B27-A469-FE1D131251E8Q36657315-1900FE98-12DD-48BD-8068-98A1DD966C06Q36667508-B910EFBB-66B9-43B0-8B22-6AE7963C2766Q36713494-0C5097FC-69CD-4E3E-9D1B-CA562390F281Q36895413-F1864B92-9C75-4C6A-A4A6-9D0B78A31A85Q36924414-895D2E2C-481B-460F-A703-3CAAC36A67C9Q37015793-FBC0350E-563F-4455-90F0-838BB81DA800Q37080967-88B65F29-4CC5-4A5B-929B-C200F86719D0Q37085804-6262FAF8-D7D5-4BCB-AF71-6AA3AE2E7616Q37098286-85841891-0F98-49BD-9DBC-9293318F36D3Q37117151-A9924D37-AA35-4116-ADB1-2331A721B456Q37175022-8489FA21-EB9A-47F3-9EA5-B62BFFC2F36CQ37293327-81F1819E-47EA-43ED-93E6-2248453EBFABQ37380746-F1C790F5-ED37-46A8-8666-93FDCBBFB495Q37523188-4F01F69E-10A6-45C5-8F36-2606ED3AA053Q37668848-72F997F3-8823-497D-99E1-C9DE8BFCC313
P2860
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Evaluation of biologic end poi ...... tor tyrosine kinase inhibitor.
@en
Evaluation of biologic end poi ...... tor tyrosine kinase inhibitor.
@nl
type
label
Evaluation of biologic end poi ...... tor tyrosine kinase inhibitor.
@en
Evaluation of biologic end poi ...... tor tyrosine kinase inhibitor.
@nl
prefLabel
Evaluation of biologic end poi ...... tor tyrosine kinase inhibitor.
@en
Evaluation of biologic end poi ...... tor tyrosine kinase inhibitor.
@nl
P2093
P50
P356
P1476
Evaluation of biologic end poi ...... tor tyrosine kinase inhibitor.
@en
P2093
Allyson L Parr
Antoinette R Tan
Arlene Berman
Catherine Chow
Erin R Lepper
Jaime S Brahim
Millie Whatley
Seth A Ettenberg
Seth M Steinberg
Stan Lipkowitz
P304
P356
10.1200/JCO.2004.08.189
P407
P577
2004-08-01T00:00:00Z